Objective: Current evidence supports symptom-triggered therapy for alcohol withdrawal
syndrome (AWS). Early, escalating therapy with benzodiazepines (BZD) appears to …

Background: There are limited data on the efficacy of symptom-triggered therapy for alcohol
withdrawal syndrome (AWS) in the intensive care unit (ICU). Objective: To evaluate the …

Background: Benzodiazepines are the gold standard for treatment of alcohol withdrawal, yet
the selection of a preferred benzodiazepine is limited due to a lack of comparative studies …

Objective To describe initial benzodiazepine dosing strategies and factors associated with
variation in benzodiazepine dosing in a national cohort of hospitalized patients with alcohol …

BACKGROUND Approximately 18% to 25% of patients with alcohol use disorders admitted
to the hospital develop alcohol withdrawal syndrome (AWS). Symptom-triggered dosing of …

Background Alcohol withdrawal accounts for a significant amount of hospital admissions
and can quickly progress to the development of delirium tremens (DTs), seizures, and death …

Background Benzodiazepine-based therapy for alcohol withdrawal is associated with
agitation and respiratory depression. Treatment can be complicated by a need for adjunctive …

Background: Alcohol withdrawal syndrome (AWS) is a common reason for admission to a
medical intensive care unit (MICU) and requires significant hospital resource utilization …

Methods This is a retrospective cohort study over a two-year period (March, 2016 to March,
2018), conducted at three hospitals within the St. Joseph Mercy Health System. We included …

Study Objective Alcohol use disorders are prevalent and put patients at risk for developing
alcohol withdrawal syndrome (AWS). Treatment of AWS with a symptom‐triggered protocol …